TLDR
- GPCR stock doubles after aleniglipron hits big in obesity drug trials.
- Structure Therapeutics reports up to 15.3% weight loss in key Phase 2 studies.
- Aleniglipron shows strong safety and results, sending GPCR shares soaring.
- New data fuels optimism for GPCR’s oral obesity treatment pipeline.
- Structure’s oral GLP-1 drug delivers a 99% jump in GPCR stock.
Structure Therapeutics (GPCR) stock surged by 99.19% to $68.84 following the release of strong Phase 2 clinical data.
Structure Therapeutics Inc., GPCR
The clinical-stage company reported significant weight loss outcomes in its ACCESS program for aleniglipron, an oral small molecule therapy. This news positioned GPCR as a major player in the growing obesity treatment market.
ACCESS Phase 2b Study Drives Momentum for GPCR
GPCR confirmed that the Phase 2b ACCESS trial met all primary and secondary endpoints with high statistical significance. The study evaluated aleniglipron in doses up to 120 mg across 230 adults with obesity or overweight conditions and comorbidities. Each dose group showed consistent results, with the 120 mg group achieving an 11.3% placebo-adjusted weight loss at Week 36.
The weight reduction reached 27.3 pounds, reinforcing the drug’s efficacy. Around 70% of participants at the highest dose lost over 10% of their body weight, demonstrating a strong dose-response trend. Aleniglipron improved blood pressure and HbA1c levels, expanding its metabolic benefit profile.
The treatment showed a tolerable safety profile similar to other GLP-1 receptor agonists. Most adverse events were gastrointestinal, appearing early and resolving over time. The average treatment discontinuation rate due to side effects remained moderate at 10.4% across active groups.
ACCESS II Study Strengthens Drug’s Competitive Edge
GPCR further advanced its case with the ACCESS II study that examined higher doses up to 240 mg. This exploratory study enrolled 85 participants and revealed even greater efficacy at higher doses without a plateau at Week 36. The 240 mg dose showed a placebo-adjusted weight loss of 15.3%, or 35.5 pounds.
Each active arm in ACCESS II surpassed placebo with p-values below 0.0001, underlining statistical strength. The response appeared consistent across doses, with greater weight reduction observed as doses increased. Participants tolerated the treatment well, with no significant new safety signals.
The company also noted that the weight loss continued to progress beyond Week 36. The drug’s performance at this stage positions it competitively against existing GLP-1 therapies, especially among oral options. The results confirmed that higher doses maintained safety while boosting effectiveness.
Supporting Studies Expand Aleniglipron’s Long-Term Potential
GPCRÂ shared interim findings from its body composition study evaluating aleniglipron’s impact on fat reduction. The 71-participant trial used a lower 2.5 mg starting dose and confirmed improved tolerability during titration. No discontinuations occurred in early phases, suggesting a viable path for gradual dosing.
This study supports flexible dosing strategies that could improve patient adherence in real-world settings. The ongoing open-label extension is tracking long-term outcomes to inform Phase 3 plans. Early trends point to sustained weight loss beyond the 36-week timeframe.
GPCR now plans to move aleniglipron into Phase 3 development. The drug’s once-daily oral format and consistent safety profile could make it a scalable and accessible option. As the company advances, it gains traction in the competitive obesity treatment space.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
